Text Size:AAA

CD25/IL2RA Protein, Antibody, ELISA Kit, cDNA Clone

Mouse CD25/IL2RA Protein

Expression host: Human Cells
  • Slide 1
50292-M08H-50
50292-M08H-100
50 µg / $178
100 µg / $298
Add to Cart

Human CD25/IL2RA Protein

Description: Active
Expression host: Human Cells
  • Slide 1
10165-H02H-50
10165-H02H-100
50 µg / $178
100 µg / $298
Add to Cart
Description: Active
Expression host: Human Cells
  • Slide 1
10165-H08H-50
10165-H08H-20
50 µg / $198
20 µg / $108
Add to Cart

Cynomolgus CD25/IL2RA Protein

Expression host: Human Cells
  • Slide 1
90265-C08H-50
90265-C08H-100
50 µg / $178
100 µg / $298
Add to Cart
Expression host: Human Cells
  • Slide 1
90265-C02H-50
90265-C02H-100
50 µg / $178
100 µg / $298
Add to Cart
Expression host: Human Cells
  • Slide 1
90265-CCCH-5
90265-CCCH-100
90265-CCCH-20
5 µg / $58
100 µg / $398
20 µg / $108
Add to Cart

CD25/IL2RA Related Areas

CD25/IL2RA Related Pathways

CD25/IL2RA Related Product

    CD25/IL2RA Summary & Protein Information

    CD25/IL2RA Related Information

    CD25/IL2RA Background

    Gene Summary: The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (CD25) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble CD25 has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced CD25 mRNAs have been isolated, but the significance of each is presently unknown. Mutations in IL2RA gene are associated with interleukin 2 receptor alpha deficiency.[provided by RefSeq, Nov 2009]
    General information above from NCBI
    Subunit structure: Non-covalent dimer of an alpha and a beta subunit. IL2R exists in 3 different forms: a high affinity dimer, an intermediate affinity monomer (beta subunit), and a low affinity monomer (alpha subunit). The high and intermediate affinity forms also associate with a gamma subunit.
    Subcellular location: Membrane; Single-pass type I membrane protein.
    Involvement in disease: Diabetes mellitus, insulin-dependent, 10 (IDDM10) [MIM:601942]: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.
    Sequence similarity: Contains 2 Sushi (CCP/SCR) domains.
    General information above from UniProt

    CD25 (alpha-chain of IL-2 receptor, or IL2RA), is a type I transmembrane glycoprotein with a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic domain. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling. The IL2RA (CD25) gene is a substantial component of the high-affinity receptor molecule highly expressed by activated T lymphocytes. Recently, a strong evidence was obtained for the involvement of IL-2RA in conferring susceptibility to type 1 diabetes (T1D). Cancer growth and development is associated with the stimulation of the innate immune system, including enhanced interleukin 2 receptor (IL-2R) expression in immune cells and its shedding into the circulation in a soluble form of sIL-2Ralpha. In most haematological malignancies, including different types of leukaemias and lymphomas, sIL-2Ralpha has been found to be released directly from the surface of neoplastic cells thus reflecting the tumour bulk, turnover and activity. Several studies have proved that not only lymphoid cancer cells, but also some non-lymphoid cancer cells, express IL-2R on their surface. They include malignant melanoma and carcinomas of the kidney, head and neck, oesophagus and lung. Thus, sIL-2Ralpha is elevated in most proliferative disturbances of the hematopoietic system and in many solid tumors.

    CD25/IL2RA Alternative Name

    CD25/IL2RA Related Studies

  • Driesen J, et al. (2008) CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. Immunobiology. 213(9-10): 849-58.
  • Olejniczak K, et al. (2008) Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review. Med Sci Monit. 14(10): RA179-89.
  • Chistiakov DA, et al. (2008) The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. Immunol Lett. 118(1): 1-5.
  • Bien E, et al. (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers. 13(1): 1-26.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"